| Name | Title | Contact Details |
|---|
BASF is a global chemical company founded in 1865 in Mannheim, Germany. Initially focused on dyes and inorganic chemicals, it has grown to become the worlds leading chemical enterprise, operating across six continents. The company emphasizes innovation, sustainability, and customer-centric solutions. BASFs diverse portfolio includes chemicals, materials, industrial solutions, surface technologies, nutrition, and agricultural solutions. It offers products such as synthetic dyes, fertilizers, polymers, crop protection products, and ingredients for the food and personal care industries. With a strong presence in various sectors like automotive, construction, and agriculture, BASF serves a wide range of customers globally. The company is committed to corporate responsibility, integrating environmental and social considerations into its operations. Its research and development efforts focus on resource efficiency, renewable energy, and principles of the circular economy. BASFs rebranding in 2015 reflects its dedication to creating sustainable solutions.
As of December 31st, 2023, the XFL has officially merged with the USFL to create the United Football League (UFL). Our spring football legacy continues in 2024 under a new name, with the same goal: to make the spring football opportunity as strong as it can be. See you at a game! theUFL.com/tickets
Assured Legacy is a health and life insurance agency that is partnered with multiple Insurance Companies to help clients find plans and policies that best fit their needs. Our Licensed Insurance Benefits Advisors guide clients through the process of assessing and understanding which benefit plans best align with their future needs and financial goals. Please visit assuredlegacy.net to learn more and schedule a no-obligation - complimentary consultation with a Licensed Insurance Benefits Advisor.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.